CytomX Therapeutics Inc.

7.60+0.0900+1.20%Vol 579.00K1Y Perf -20.25%
Apr 19th, 2021 16:00 DELAYED
BID7.18 ASK7.64
Open7.41 Previous Close7.51
Pre-Market- After-Market7.60
 - -  - -%
Target Price
14.80 
Analyst Rating
Strong Buy 1.44
Potential %
94.74 
Finscreener Ranking
★★★     50.99
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
     42.17
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★+     49.49
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Market Cap492.36M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
14.69 
Earnings Date
6th May 2021

Today's Price Range

7.397.65

52W Range

6.2515.44

5 Year PE Ratio Range

-10.70-4.40

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
11.27%
1 Month
-8.10%
3 Months
-6.75%
6 Months
13.26%
1 Year
-20.25%
3 Years
-71.86%
5 Years
-43.24%
10 Years
-

TickerPriceChg.Chg.%
CTMX7.600.09001.20
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
Financial StrengthValueIndustryS&P 500US Markets
3.10
3.20
0.30
0.50
-
Leverage Ratio 7.00
ProfitabilityValueIndustryS&P 500US Markets
-
-68.30
-65.50
-159.20
-88.81
RevenueValueIndustryS&P 500US Markets
50.77M
0.78
9.13
59.61
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.35-0.3111.43
Q03 2020-0.36-0.3211.11
Q02 20200.34-0.34-200.00
Q01 2020-0.340.26176.47
Q04 2019-0.55-0.79-43.64
Q03 2019-0.39-0.52-33.33
Q02 2019-0.55-0.64-16.36
Q01 2019-0.53-0.3141.51
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.2929.27Positive
6/2021 QR-0.3036.17Positive
12/2021 FY-1.2431.11Positive
12/2022 FY-1.5426.67Positive
Next Report Date6th May 2021
Estimated EPS Next Report-0.29
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume579.00K
Shares Outstanding64.78M
Trades Count4.79K
Dollar Volume5.91M
Avg. Volume1.01M
Avg. Weekly Volume982.51K
Avg. Monthly Volume898.27K
Avg. Quarterly Volume1.11M

CytomX Therapeutics Inc. (NASDAQ: CTMX) stock closed at 7.6 per share at the end of the most recent trading day (a 1.2% change compared to the prior day closing price) with a volume of 579.01K shares and market capitalization of 492.36M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 146 people. CytomX Therapeutics Inc. CEO is Sean A. McCarthy.

The one-year performance of CytomX Therapeutics Inc. stock is -20.25%, while year-to-date (YTD) performance is 16.03%. CTMX stock has a five-year performance of -43.24%. Its 52-week range is between 6.25 and 15.44, which gives CTMX stock a 52-week price range ratio of 14.69%

CytomX Therapeutics Inc. currently has a PE ratio of -10.60, a price-to-book (PB) ratio of 9.77, a price-to-sale (PS) ratio of 9.70, a price to cashflow ratio of 65.90, a PEG ratio of 2.32, a ROA of -9.01%, a ROC of -61.04% and a ROE of -62.37%. The company’s profit margin is -88.81%, its EBITDA margin is -65.50%, and its revenue ttm is $50.77 Million , which makes it $0.78 revenue per share.

Of the last four earnings reports from CytomX Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.29 for the next earnings report. CytomX Therapeutics Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for CytomX Therapeutics Inc. is Strong Buy (1.44), with a target price of $14.8, which is +94.74% compared to the current price. The earnings rating for CytomX Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CytomX Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CytomX Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.16, ATR14 : 0.57, CCI20 : -38.61, Chaikin Money Flow : 0.08, MACD : -0.15, Money Flow Index : 50.10, ROC : -1.68, RSI : 51.78, STOCH (14,3) : 57.29, STOCH RSI : 0.95, UO : 53.33, Williams %R : -42.71), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CytomX Therapeutics Inc. in the last 12-months were: Sean A. McCarthy (Option Excercise at a value of $289 812), Sean A. McCarthy (Sold 36 000 shares of value $540 000 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (77.78 %)
8 (88.89 %)
8 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (22.22 %)
1 (11.11 %)
2 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.44
Strong Buy
1.22
Strong Buy
1.40

CytomX Therapeutics Inc.

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities.

CEO: Sean A. McCarthy

Telephone: +1 650 515-3185

Address: 151 Oyster Point Boulevard, South San Francisco 94080, CA, US

Number of employees: 146

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

56%44%

Bearish Bullish

59%41%

News

Stocktwits